Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCMNASDAQ:CYADCVE:CYPNASDAQ:NBSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$5.70+3.4%$6.86$3.80▼$10.90$24.88M-0.916,239 shs1,634 shsCYADCelyad$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsCYPCypress DevelopmentC$1.09+1.4%C$1.09C$0.84▼C$2.14C$35.88MN/A71,527 shs33,605 shsNBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services-0.52%-0.52%-17.87%+37.85%-43.00%CYADCelyad0.00%0.00%0.00%0.00%0.00%CYPCypress Development0.00%0.00%0.00%0.00%0.00%NBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCMConcord Medical ServicesN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AN/AN/AN/ACYPCypress DevelopmentN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCMConcord Medical Services 0.00N/AN/AN/ACYADCelyad 0.00N/AN/AN/ACYPCypress Development 0.00N/AN/AN/ANBSENeuBase Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCMConcord Medical Services$52.60M0.47N/AN/A$51.05 per share0.11CYADCelyad$200K79.56N/AN/A$0.02 per share30.00CYPCypress DevelopmentN/AN/AC$0.24 per share4.49C$0.36 per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/ACYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/ACYPCypress Development-C$735.02K-C$0.10N/A∞N/AN/A-6.17%N/AN/ANBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCMConcord Medical ServicesN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/ACYPCypress DevelopmentN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCMConcord Medical Services1.670.460.45CYADCelyad1.492.292.14CYPCypress Development0.6917.5642.15NBSENeuBase TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCMConcord Medical ServicesN/ACYADCelyadN/ACYPCypress DevelopmentN/ANBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipCCMConcord Medical Services46.50%CYADCelyad0.94%CYPCypress DevelopmentN/ANBSENeuBase Therapeutics7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableCYADCelyad9526.52 million26.28 millionNot OptionableCYPCypress DevelopmentN/A32.92 millionN/ANot OptionableNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionableCCM, NBSE, CYAD, CYP, and AC8 HeadlinesRecent News About These CompaniesGreenlight Capital Q3 2024 LetterOctober 17, 2024 | seekingalpha.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 13, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekMay 6, 2024 | bizjournals.comNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 6, 2024 | finanznachrichten.deNeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comOnce-promising Pittsburgh biotech firm shutting down for goodMarch 27, 2024 | technical.lyTWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 27, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | msn.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 26, 2024 | investorplace.comNeuBase Therapeutics sets shareholder meeting on dissolution planMarch 25, 2024 | bizjournals.comNeuBase Therapeutics IncFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics, Inc. (NBSE)February 20, 2024 | finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)January 19, 2024 | ca.finance.yahoo.comMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsJanuary 1, 2024 | knoxdaily.comKCMU halts licensing agreement with NeuBase TherapeuticsDecember 22, 2023 | bizjournals.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 27, 2023 | finance.yahoo.comNeuBase Therapeutics Inc NBSENovember 6, 2023 | morningstar.comMNeuBase Therapeutics: Other EventsOctober 21, 2023 | cbonds.comCNeuBase Therapeutics, Inc. (NBSE.MX)October 6, 2023 | finance.yahoo.comNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. WainwrightSeptember 20, 2023 | knoxdaily.comKMedia Sentiment Over TimeCCM, NBSE, CYAD, CYP, and AC8 Company DescriptionsConcord Medical Services NYSE:CCM$5.70 +0.19 (+3.45%) Closing price 07/1/2025 03:45 PM EasternExtended Trading$5.70 0.00 (0.00%) As of 07/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Celyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Cypress Development CVE:CYPC$1.09 +0.02 (+1.40%) As of 01/27/2023Cypress Development Corp. engages in the acquisition, exploration, evaluation, and development of mineral properties in the United States and Canada. It explores for lithium, zinc, and silver deposits. The company's flagship project is the Clayton Valley project that covers an area of approximately 5,430 acres located in southwest Nevada. Cypress Development Corp. was incorporated in 1991 and is headquartered in Vancouver, Canada.NeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
